UK biotech OMass Therapeutics closed an oversubscribed $310 million Series C to advance its endocrinology and immunology programs, led by OMS1620 in Phase II for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. Proceeds also support early work on SLC15A4, an interferon-pathway targeted inhibitor across lupus and related conditions.